Adlai Nortye Investor Relations Material

Adlai Nortye Ltd. is a global clinical-stage biopharmaceutical company primarily engaged in developing innovative immuno-oncology medicines. The company's mission is to improve patient lives by discovering and developing differentiated innovative treatments for cancer. It has a strategic focus on oncology, with research and development and global clinical operation centers located in the United States and China. The company is headquartered in North Brunswick, New Jersey, and its shares are listed on the Nasdaq.